entertainment -WSS

entertainment

author：knowledge 2025-08-19 12:15:12 - browse：142

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Akero's treatment for NASH falls short in cirrhosis study

entertainment

WSS

Reporting on presidential health from Reagan to Trump and Biden

Wellcome Trust names Røttingen as its new CEO

Akero's treatment for NASH falls short in cirrhosis study

How should state employee insurance handle Wegovy?

Wellcome Trust names Røttingen as its new CEO

New study raises questions about niacin and heart health

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Heart attack and stroke risk calculators need revising

European regulators consider appeal over Amylyx ALS drug

Medicare details structure of new drug price negotiation program

New study raises questions about niacin and heart health

Medical records are filled with copy

Hospitals are piloting generative AI tools as regulators play catch

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

23andMe had bad news about my health. I wish a person had delivered it

Better Therapeutics data on benefit with GLP

focus

Medicare to cover more brain scans related to Alzheimer’s drugs

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Medicare Advantage enrollment hits roughly 33.4 million

Peter Marks talks Operation Warp Speed for Rare Diseases

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

In 'major milestone,' FDA approves first cell therapy for solid tumors

leisure time

hotspot

entertainment

entertainment